Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Atezolizumab (Tecentriq)

Published September 20, 2022

Key Messages

  • CADTH recommends that Tecentriq, in combination with a platinum-based chemotherapy and etoposide, should be reimbursed by public drug plans for the treatment of extensive-stage small cell lung cancer (ES-SCLC) if certain conditions are met.
  • Tecentriq should only be covered to treat adult patients who have not received previous treatment for ES-SCLC and who are in relatively good health.
  • Tecentriq should only be reimbursed when used in combination with platinum-based chemotherapy and etoposide if it is prescribed and patients are monitored by clinicians with expertise in managing ES-SCLC, and if the price of Tecentriq leads to cost savings for the public drug plans.